What happened, in summary

A 50-year-old woman had been diagnosed three years earlier with ovarian cancer. One year after diagnosis, she underwent removal of the left ovary and fallopian tube, with pathology showing high-grade serous ovarian carcinoma. Postoperative imaging showed peritoneal carcinomatosis and ascites.

She received six cycles of paclitaxel plus carboplatin without meaningful benefit. Because the disease was platinum-resistant, treatment changed to paclitaxel plus bevacizumab. She initially improved after two cycles and stopped treatment, but restarted when her condition worsened four months later. Genetic evaluation identified a BRCA1 variant of uncertain significance, which was not treated as a confirmed pathogenic mutation.

As the cancer continued to spread, later treatment included two cycles of topotecan followed by two cycles of carboplatin, without success. She developed severe illness with bowel obstruction symptoms, prolonged vomiting and abdominal pain and eventually entered a palliative oncology unit. She died 2.5 years after her ovarian-cancer diagnosis.